Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of Poziotinib in Combination With T-DM1 in Women With Advanced or Metastatic HER2-Positive Breast Cancer

NCT03429101 is registered in ClinicalTrials.gov with Spectrum Pharmaceuticals, Inc as lead sponsor.

NCT NCT03429101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03429101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of Poziotinib in Combination With T-DM1 in Women With Advanced or Metastatic HER2-Positive Breast Cancer
Lead sponsor
Spectrum Pharmaceuticals, Inc
Phase
Phase 1
Overall status
Terminated
Start date
July 13, 2018
Completion date
April 17, 2019
Enrollment
6 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer